Potassium Disorders - Pathophysiology

SECTION 1

Historical Context & Motivation

The recognition of potassium as a distinct element dates to the early nineteenth century, but its clinical significance in human physiology took over a century to unravel. Potassium is the most abundant intracellular cation in the human body, and even modest deviations in its serum concentration can provoke life-threatening cardiac arrhythmias. The journey from the elemental isolation of potassium to modern-day electrolyte panels illustrates how chemistry, physiology, and clinical medicine converge around a single ion. Understanding this history provides the foundation for appreciating why potassium homeostasis remains one of the most closely monitored parameters in critical care, nephrology, and emergency medicine.

1807 • Isolation of Potassium

Sir Humphry Davy isolated potassium from caustic potash (KOH) by electrolysis, making it the first metal isolated by this technique. The element's name derives from "potash," connecting it to the plant-ash fertilizers long used in agriculture.

1883 • Ringer's Solution

Sydney Ringer demonstrated that an isolated frog heart required calcium and potassium ions in precise concentrations to maintain rhythmic contractions. This landmark experiment established potassium as essential for cardiac function and launched the field of electrolyte physiology.

1952 • Hodgkin–Huxley Model

Alan Hodgkin and Andrew Huxley published their mathematical model of the action potential in the squid giant axon, quantifying the roles of sodium and potassium conductances. Their Nobel Prize–winning work cemented potassium's role in membrane excitability.

1957 • Na⁺/K⁺-ATPase Discovery

Jens Christian Skou identified the Na⁺/K⁺-ATPase pump, the molecular engine that maintains the potassium gradient across cell membranes. This discovery, which earned Skou the Nobel Prize in Chemistry in 1997, explained how cells actively partition potassium intracellularly.

1990s–Present • Clinical Electrolyte Management

Advances in point-of-care testing, ion-selective electrode technology, and evidence-based guidelines have transformed the diagnosis and treatment of hypokalemia and hyperkalemia, making rapid potassium measurement routine in emergency and critical care settings.

The central question that emerges from this history is deceptively simple: how does the body maintain serum potassium within a remarkably narrow range of 3.5–5.0 mEq/L despite large dietary fluctuations and continuous cellular exchange? When this regulation fails—whether through renal dysfunction, hormonal imbalance, or iatrogenic causes—the resulting hypokalemia or hyperkalemia can rapidly become a medical emergency. The remainder of this lesson explores the pathophysiology, clinical manifestations, and management of these disorders.

SECTION 2

Core Principles of Potassium Homeostasis

Potassium homeostasis depends on a tightly coordinated interplay between dietary intake, internal transcellular shifts, and renal excretion. Approximately 98% of total body potassium resides within cells—primarily in skeletal muscle—while only 2% occupies the extracellular fluid (ECF). This steep intracellular-to-extracellular gradient is maintained by the Na⁺/K⁺-ATPase, which pumps 3 Na⁺ ions out and 2 K⁺ ions into the cell for every molecule of ATP hydrolyzed. Because the serum potassium concentration reflects only the extracellular fraction, small absolute shifts between compartments can produce dramatic changes in measured serum levels. Understanding these foundational principles is essential before examining the specific pathophysiology of hypokalemia and hyperkalemia.

Na⁺/K⁺-ATPase Gradient

The Na⁺/K⁺-ATPase actively pumps potassium into cells and sodium out, establishing the 140 mEq/L intracellular versus 4 mEq/L extracellular potassium gradient that is essential for the resting membrane potential.

Internal Balance (Transcellular Shifts)

Insulin, β₂-adrenergic stimulation, and alkalosis drive potassium into cells. Conversely, acidosis, hyperosmolality, cell lysis, and α-adrenergic stimulation promote potassium efflux into the ECF.

External Balance (Renal Excretion)

The kidneys eliminate approximately 90% of daily potassium intake, primarily through secretion in the cortical collecting duct. Aldosterone is the chief hormonal regulator, stimulating principal cell K⁺ secretion via ENaC and ROMK channels.

Resting Membrane Potential

The resting membrane potential (approximately −90 mV in cardiac myocytes) is determined largely by the K⁺ gradient across the cell membrane via the Nernst equation. Alterations in serum K⁺ shift this potential, directly affecting cellular excitability.

Acid–Base Coupling

Potassium and hydrogen ions compete for renal secretion and transcellular exchange. Metabolic alkalosis promotes hypokalemia while metabolic acidosis (non-anion-gap) tends to elevate serum potassium through H⁺/K⁺ exchange across cell membranes.

✦

KEY TAKEAWAY

Think of potassium distribution like a warehouse system: 98% of inventory is in a massive storage facility (the intracellular space) while only 2% sits on the loading dock (the ECF). Serum potassium measurements only count what is on the loading dock. Even a small shift of crates between warehouse and dock—triggered by insulin, pH changes, or catecholamines—can dramatically change the dock count without altering total inventory. This is why transcellular shifts can produce clinically significant hypokalemia or hyperkalemia even when total body potassium is normal.

SECTION 3

Visual Explanation: Potassium Distribution & Regulation

This diagram illustrates the two-compartment model of potassium distribution. The left panel (violet) represents the intracellular fluid containing 98% of body potassium at approximately 140 mEq/L. The right panel (cyan) represents the extracellular fluid at 3.5–5.0 mEq/L. The Na⁺/K⁺-ATPase actively maintains this gradient. Factors shifting potassium into cells (green) and out of cells (red) are listed, while the lower box highlights that the kidneys handle roughly 90% of daily potassium elimination under aldosterone regulation.

As illustrated above, potassium homeostasis can be conceptualized through two regulatory axes: internal balance (transcellular shifts between ICF and ECF) and external balance (renal and gastrointestinal elimination). The internal balance provides rapid minute-to-minute buffering after a potassium-rich meal; insulin released postprandially drives K⁺ into skeletal muscle and hepatocytes, preventing dangerous transient hyperkalemia. The external balance operates over hours through aldosterone-mediated renal secretion in the cortical collecting duct. When either axis is disrupted—whether by renal failure impairing excretion, loop diuretics enhancing excretion, or diabetic ketoacidosis causing transcellular shifts—the serum potassium concentration deviates from its narrow physiological range, producing the clinical syndromes of hypokalemia or hyperkalemia.

SECTION 4

Mechanisms of Potassium Disorders

The Nernst Equation and Membrane Potential

The clinical significance of potassium disorders is rooted in the relationship between the potassium concentration gradient and the resting membrane potential (V_m). The Nernst equation quantifies the equilibrium potential for potassium across a semipermeable membrane. Because potassium conductance dominates at rest in both cardiac myocytes and skeletal muscle, V_m closely approximates the K⁺ equilibrium potential (E_K).

NERNST EQUATION FOR POTASSIUM

E_K = (RT / zF) × ln([K⁺]_out / [K⁺]_in)

Where R = gas constant (8.314 J/mol·K), T = temperature in Kelvin (310 K at body temperature), z = valence of K⁺ (+1), F = Faraday constant (96,485 C/mol). At 37°C this simplifies to E_K ≈ −61.5 mV × log₁₀([K⁺]_out / [K⁺]_in).

Hypokalemia: Mechanisms of Development

Hypokalemia (serum K⁺ < 3.5 mEq/L) arises through three primary mechanisms: decreased intake, increased renal or gastrointestinal losses, and transcellular shift of K⁺ into cells. Renal losses are the most common cause and frequently result from diuretic use—particularly loop and thiazide diuretics—which increase distal tubular flow and enhance K⁺ secretion. Primary hyperaldosteronism similarly augments renal K⁺ wasting via upregulation of ENaC and ROMK channels. Gastrointestinal losses from vomiting or diarrhea can produce severe hypokalemia; notably, vomiting causes hypokalemia primarily through renal mechanisms (metabolic alkalosis and volume contraction) rather than direct gastric K⁺ loss.

Hyperkalemia: Mechanisms of Development

Hyperkalemia (serum K⁺ > 5.0 mEq/L) develops through decreased renal excretion, excessive intake or release, or transcellular shift of K⁺ out of cells. The kidneys possess enormous capacity to excrete potassium, so clinically significant hyperkalemia almost always involves some degree of impaired renal function—acute kidney injury, chronic kidney disease (especially with GFR < 15 mL/min), or medications that impair the renin-angiotensin-aldosterone system (ACE inhibitors, ARBs, spironolactone). Massive cellular release from rhabdomyolysis, tumor lysis syndrome, or severe burns can overwhelm even normal renal capacity. Importantly, pseudohyperkalemia—an artifactual elevation caused by hemolysis during blood draw or prolonged tourniquet time—must always be excluded before initiating treatment.

TRANSTUBULAR POTASSIUM GRADIENT (TTKG)

TTKG = (Urine K⁺ / Serum K⁺) / (Urine Osm / Serum Osm)

The TTKG estimates the potassium concentration in the cortical collecting duct relative to peritubular capillary blood. A TTKG > 7 in hyperkalemia suggests appropriate renal K⁺ secretion, while a TTKG < 7 in the setting of hyperkalemia suggests impaired renal excretion as the cause, implicating aldosterone deficiency or resistance.

SECTION 5

Classification & Clinical Manifestations

Potassium disorders are classified by severity and by the direction of the derangement. The clinical manifestations of both hypokalemia and hyperkalemia reflect altered membrane excitability in cardiac, skeletal muscle, and smooth muscle tissues. The following diagram and table organize the ECG findings, neuromuscular symptoms, and severity grades for each disorder.

This diagram shows the potassium spectrum from severe hypokalemia (< 2.5 mEq/L) to severe hyperkalemia (> 6.5 mEq/L) with the normal range (3.5–5.0 mEq/L) centered in green. The lower panels display characteristic ECG changes: hypokalemia produces ST depression, T-wave flattening, and prominent U waves, whereas hyperkalemia classically produces peaked T waves progressing to QRS widening and sine-wave patterns. Simplified ECG waveform tracings illustrate these hallmark morphologies.

Feature	Hypokalemia (K⁺ < 3.5 mEq/L)	Hyperkalemia (K⁺ > 5.0 mEq/L)
Cardiac	Atrial & ventricular arrhythmias, PVCs, torsades de pointes, U waves, ST depression, T-wave flattening	Peaked T waves, PR prolongation, P-wave loss, QRS widening, sine wave → asystole/V-fib
Neuromuscular	Muscle weakness, cramps, fatigue, hyporeflexia; severe: ascending paralysis, rhabdomyolysis	Muscle weakness, paresthesias, ascending paralysis (in severe cases)
GI	Constipation, ileus (smooth muscle dysfunction)	Nausea, vomiting, diarrhea (variable)
Renal	Nephrogenic diabetes insipidus, metabolic alkalosis, impaired urinary concentration	Metabolic acidosis (type 4 RTA if due to hypoaldosteronism)
Membrane Potential	Hyperpolarized (more negative Vₘ) → decreased excitability	Depolarized (less negative Vₘ) → initial excitability then inexcitability

Comparison of clinical manifestations in hypokalemia vs. hyperkalemia

SECTION 6

Worked Clinical Example

The following worked example demonstrates the systematic approach to evaluating and managing a patient presenting with a potassium disorder. This clinical reasoning framework integrates history, lab values, ECG interpretation, and evidence-based treatment.

Managing Acute Hyperkalemia in a Patient with CKD

1
Step 1 — Assess the Clinical Scenario

A 68-year-old patient with stage 4 CKD (eGFR 18 mL/min) presents to the emergency department with generalized weakness and palpitations. Medications include lisinopril, spironolactone, and a potassium-containing salt substitute. A stat basic metabolic panel returns: serum K⁺ = 7.2 mEq/L, creatinine 4.1 mg/dL, HCO₃⁻ 18 mEq/L.

Severe hyperkalemia (K⁺ 7.2 mEq/L) — this is an emergency.
2
Step 2 — Identify Contributing Factors

Three factors converge: (1) Decreased renal excretion due to stage 4 CKD with severely reduced GFR; (2) Impaired RAAS from lisinopril (ACE inhibitor) and spironolactone (aldosterone antagonist), both of which reduce renal K⁺ secretion; (3) Increased K⁺ intake from a potassium-containing salt substitute. The metabolic acidosis (HCO₃⁻ 18) promotes additional transcellular shift of K⁺ out of cells.

Multifactorial etiology: decreased excretion + RAAS blockade + increased intake + acidosis-driven transcellular shift.
3
Step 3 — Evaluate the ECG

The 12-lead ECG reveals peaked T waves in leads V2–V5, a widened QRS at 140 ms (normal < 120 ms), and loss of P waves. This pattern indicates that hyperkalemia has depressed atrial conduction and slowed ventricular depolarization. These are late and dangerous ECG changes, placing the patient at risk for deterioration into a sine-wave pattern, ventricular fibrillation, or asystole.

ECG shows peaked T waves, QRS widening, and absent P waves — immediate intervention required.
4
Step 4 — Initiate Treatment (Temporizing Measures)

Treatment of severe hyperkalemia with ECG changes proceeds in three tiers: (A) Cardiac membrane stabilization: IV calcium gluconate (10 mL of 10% solution over 2–3 minutes) to antagonize the effect of K⁺ on the myocardium. This does not lower K⁺ but protects the heart within minutes. (B) Intracellular K⁺ shift: Regular insulin (10 units IV) with dextrose (25 g IV) to drive K⁺ into cells; onset 15–30 minutes. Inhaled albuterol (10–20 mg nebulized) provides an additive β₂-mediated shift. IV sodium bicarbonate if significant acidosis persists. (C) K⁺ removal from the body: Sodium polystyrene sulfonate (Kayexalate) or patiromer orally for GI potassium binding; emergent hemodialysis if refractory.

Priority: stabilize → shift → remove. Calcium gluconate first, then insulin/dextrose + albuterol, then dialysis consultation.
5
Step 5 — Address the Root Cause and Prevent Recurrence

After acute stabilization, the offending agents must be addressed. Lisinopril and spironolactone should be discontinued or dose-reduced, and the patient should be counseled to avoid potassium-containing salt substitutes. A low-potassium diet (< 2 g/day) should be instituted. The patient's nephrologist should be consulted regarding chronic potassium management, potential use of newer potassium binders (patiromer, sodium zirconium cyclosilicate), and preparation for renal replacement therapy given stage 4 CKD. Serum potassium should be rechecked every 1–2 hours until stable below 5.5 mEq/L.

Stop offending medications, dietary counseling, nephrology consultation, and serial potassium monitoring.

SECTION 7

Treatment Approaches: Strengths & Limitations

Effective management of potassium disorders requires matching the urgency of the clinical situation to the appropriate intervention. The following table compares the major therapeutic agents used in both hypokalemia and hyperkalemia, highlighting their mechanism, onset, and key limitations. No single intervention is sufficient in isolation for severe potassium derangements; rather, a layered approach using agents from different mechanistic categories produces the most reliable outcomes.

Intervention	Mechanism	Onset / Duration	Limitations
IV Calcium Gluconate	Stabilizes cardiac membrane; does NOT lower serum K⁺	1–3 min onset; lasts 30–60 min	Transient effect; must repeat if ECG changes persist. Caution with digitalis use.
Insulin + Dextrose	Activates Na⁺/K⁺-ATPase → shifts K⁺ intracellularly	15–30 min onset; lasts 4–6 h	Risk of hypoglycemia; monitor glucose q1h × 4h. Redistributes but does not eliminate K⁺.
Nebulized Albuterol	β₂-agonist → stimulates Na⁺/K⁺-ATPase, shifts K⁺ into cells	30 min onset; lasts 2–4 h	Requires high doses (10–20 mg). Tachycardia risk. ~40% of patients are partial non-responders.
Hemodialysis	Directly removes K⁺ from blood across the dialysis membrane	Immediate during treatment	Requires vascular access and dialysis nursing. Rebound hyperkalemia post-dialysis possible.
Oral/IV KCl (for hypokalemia)	Directly replaces K⁺ deficit	Oral: 1–2 h; IV: immediate	IV rate max 10–20 mEq/h (peripheral line); must monitor for overcorrection. Oral can cause GI irritation.
Patiromer / SZC	Cation-exchange agents binding K⁺ in the GI tract for fecal elimination	4–7 h onset	Slow onset—not suitable for acute emergencies. May cause constipation (patiromer) or edema (SZC).

Comparison of interventions for potassium disorders

✦

KEY TAKEAWAY

Think of treating severe hyperkalemia like fighting a house fire: calcium gluconate is the fireproof suit—it protects the heart immediately but doesn't put out the fire. Insulin/dextrose and albuterol are like pushing the fire back behind a door—they shift potassium into cells, buying time. But only dialysis or GI binders actually remove potassium from the body, analogous to extinguishing the fire at its source. Effective management always requires layering these approaches in parallel, not sequentially.

SECTION 8

Connection to Advanced Pathophysiology

Potassium disorders do not exist in isolation; they intersect with nearly every organ system and are commonly encountered alongside other electrolyte and acid–base derangements. Mastering foundational potassium pathophysiology positions students to engage with advanced topics in nephrology, endocrinology, and critical care medicine. The table below maps how foundational concepts extend into more complex clinical territory.

Foundational Concept	Advanced Extension
Aldosterone regulates K⁺ secretion in the CCD	Primary hyperaldosteronism (Conn syndrome) causes refractory hypokalemia with hypertension; type 4 RTA from hypoaldosteronism causes chronic hyperkalemia with mild metabolic acidosis
Acid–base coupling with potassium	DKA presents with hyperkalemia from transcellular shift despite severe total body K⁺ depletion; insulin therapy rapidly corrects acidosis and can precipitate dangerous hypokalemia if K⁺ is not repleted concurrently
Nernst equation and membrane excitability	The Goldman-Hodgkin-Katz equation extends the Nernst equation to multi-ion systems, modeling how combined Na⁺, K⁺, and Cl⁻ permeabilities shape the action potential in cardiac tissue and explain arrhythmia substrates
Na⁺/K⁺-ATPase and transcellular shifts	Digitalis glycosides (digoxin) inhibit the Na⁺/K⁺-ATPase; digitalis toxicity is potentiated by hypokalemia because K⁺ and digoxin compete for the same binding site on the pump
Renal K⁺ handling and diuretics	Bartter syndrome and Gitelman syndrome are inherited tubulopathies that mimic loop and thiazide diuretic effects, respectively, producing chronic hypokalemia and metabolic alkalosis

Foundational potassium concepts mapped to advanced clinical topics

Looking ahead, advanced renal physiology coursework will explore the molecular mechanisms of ENaC, ROMK, and BK channels in the cortical collecting duct, as well as the WNK–SPAK kinase signaling pathway that integrates sodium and potassium handling with blood pressure regulation. In critical care, students will encounter complex scenarios involving simultaneous correction of potassium, magnesium, and calcium in the context of massive transfusion, cardiopulmonary bypass, and organ transplantation. The foundational principles covered in this lesson—membrane potential dependence on K⁺ gradients, the three-axis model of intake, shift, and excretion, and the clinical urgency of ECG changes—form the scaffold upon which these advanced topics are built.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A patient with diabetic ketoacidosis (DKA) presents with a serum K⁺ of 5.8 mEq/L. Despite this elevated reading, the treating physician states that the patient is actually profoundly depleted in total body potassium. Explain the physiological basis for this apparent contradiction and describe why K⁺ must be closely monitored once insulin therapy begins.

Show answer

In DKA, multiple mechanisms drive potassium from the intracellular to the extracellular space: insulin deficiency removes the stimulus for Na⁺/K⁺-ATPase–mediated cellular K⁺ uptake, metabolic acidosis promotes H⁺/K⁺ exchange across cell membranes, and hyperosmolality from hyperglycemia draws water and K⁺ out of cells via solvent drag. Meanwhile, the osmotic diuresis and vomiting associated with DKA cause massive renal and GI potassium losses, depleting total body K⁺ even as the serum level appears elevated. When insulin is administered, it rapidly drives K⁺ back into cells, unmasking the true deficit and potentially causing dangerous hypokalemia. Therefore, K⁺ should be checked every 1–2 hours during insulin infusion, and potassium replacement should be initiated when serum K⁺ falls below 5.3 mEq/L (or before starting insulin if K⁺ < 3.3 mEq/L).

Question 2: BASIC CALCULATION

Using the simplified Nernst equation at 37°C (E_K = −61.5 mV × log₁₀([K⁺]_out / [K⁺]_in)), calculate the potassium equilibrium potential (E_K) for a normal cardiac myocyte with [K⁺]_out = 4.0 mEq/L and [K⁺]_in = 140 mEq/L. Then recalculate for a patient with hyperkalemia where [K⁺]_out = 7.0 mEq/L. What is the change in E_K and what is the clinical significance?

Show answer

Normal: E_K = −61.5 × log₁₀(4/140) = −61.5 × log₁₀(0.0286) = −61.5 × (−1.544) = −94.9 mV. Hyperkalemia: E_K = −61.5 × log₁₀(7/140) = −61.5 × log₁₀(0.05) = −61.5 × (−1.301) = −80.0 mV. The E_K shifts from −94.9 mV to −80.0 mV, a depolarization of approximately 15 mV. This means the resting membrane potential becomes less negative (depolarized), moving closer to the threshold potential. Initially this increases excitability, but sustained depolarization inactivates voltage-gated sodium channels, ultimately reducing excitability and slowing conduction—the mechanism behind the widened QRS and risk of cardiac arrest in severe hyperkalemia.

Question 3: INTERMEDIATE

A 55-year-old woman on hydrochlorothiazide for hypertension presents with muscle cramps and weakness. Labs show: K⁺ 2.9 mEq/L, Mg²⁺ 1.4 mg/dL (normal 1.7–2.2), HCO₃⁻ 31 mEq/L. You administer IV potassium chloride but the K⁺ remains stubbornly low despite adequate supplementation. What is the most likely explanation, and what additional intervention is required?

Show answer

The most likely explanation is concurrent hypomagnesemia. Magnesium is a cofactor for the Na⁺/K⁺-ATPase and also regulates the ROMK channel in the cortical collecting duct. When magnesium is depleted, the ROMK channel becomes "leaky," promoting excessive renal potassium wasting that persists regardless of how much potassium is supplemented. This is a commonly tested clinical pearl: hypokalemia that is refractory to potassium replacement indicates the need to check and correct the serum magnesium. The patient requires IV magnesium sulfate (1–2 g over 1 hour, then continued oral supplementation) alongside continued potassium repletion. Additionally, the metabolic alkalosis (HCO₃⁻ 31) driven by the thiazide diuretic promotes transcellular K⁺ shift into cells and enhances renal K⁺ secretion, compounding the problem.

Question 4: APPLIED

You are a nurse on a telemetry floor and receive a critical lab alert: K⁺ 6.8 mEq/L on a patient with stage 3 CKD who was admitted for cellulitis. The patient's ECG shows peaked T waves but a normal QRS width. Outline your prioritized actions, including which physician orders you would anticipate, the rationale for each intervention, and the monitoring parameters you would institute.

Show answer

First, confirm the result is not pseudohyperkalemia by assessing the specimen quality (no hemolysis, not drawn above an IV potassium infusion, minimal tourniquet time). If confirmed, immediately notify the provider. Anticipated orders: (1) Continuous cardiac monitoring and repeat stat ECG. (2) IV calcium gluconate 10 mL of 10% solution over 2–3 min for cardiac stabilization given ECG changes; repeat in 5 minutes if peaked T waves persist. (3) Regular insulin 10 units IV + 25 g dextrose IV to drive K⁺ into cells; monitor blood glucose every 30–60 minutes for hypoglycemia. (4) Nebulized albuterol 10 mg for additional transcellular K⁺ shift. (5) Hold any K⁺-sparing medications, ACE inhibitors, or ARBs. (6) Consider sodium polystyrene sulfonate or patiromer for GI K⁺ removal. (7) Recheck serum K⁺ in 1–2 hours. If refractory, notify nephrology for emergent dialysis. Monitoring parameters include continuous telemetry, serial K⁺ every 1–2 hours, serial ECGs, hourly blood glucose for 4 hours after insulin administration, and urine output.

Question 5: CRITICAL THINKING

A patient with end-stage renal disease on thrice-weekly hemodialysis consistently presents with serum K⁺ of 6.0–6.5 mEq/L before each dialysis session, yet remains asymptomatic with a normal ECG. A different patient with normal renal function develops ventricular fibrillation with a serum K⁺ of 6.2 mEq/L during a massive blood transfusion. Discuss why the clinical impact of the same serum potassium level can differ so dramatically between these two patients. Consider the roles of chronicity, acid–base status, calcium, and rate of change in your analysis.

Show answer

The key concept is that the cardiac toxicity of hyperkalemia depends not only on the absolute serum K⁺ level but also on the rate of rise, the chronicity of exposure, and concomitant electrolyte and acid–base conditions. In the ESRD patient, potassium rises slowly over 48–72 hours between dialysis sessions. This gradual increase allows time for cellular adaptation: cardiac myocytes and other excitable tissues adjust their ion channel expression and resting membrane potential, increasing tolerance. In contrast, during massive transfusion, the K⁺ load from stored packed red blood cells (which undergo potassium leakage during storage) is delivered rapidly into the intravascular space. The rate of rise is far more abrupt, and the cardiac conduction system has no time to adapt. Furthermore, massive transfusion often produces hypothermia, citrate-induced hypocalcemia, and acidosis from citrate metabolism—all of which potentiate the cardiac effects of hyperkalemia. Hypocalcemia is particularly synergistic because calcium normally stabilizes the cardiac membrane; its depletion lowers the threshold at which hyperkalemia causes arrhythmias. This case illustrates why clinicians must interpret potassium values in clinical context rather than treating numbers in isolation, and why the rate of change can be more dangerous than the absolute value.

SUMMARY

Potassium Disorders — Summary

Summary

Potassium disorders encompass hypokalemia (K⁺ < 3.5 mEq/L) and hyperkalemia (K⁺ > 5.0 mEq/L), both of which can produce life-threatening cardiac arrhythmias and neuromuscular dysfunction. The body maintains serum potassium within a narrow 3.5–5.0 mEq/L range through the interplay of dietary intake, Na⁺/K⁺-ATPase–mediated transcellular shifts (modulated by insulin, catecholamines, and acid–base status), and aldosterone-regulated renal excretion in the cortical collecting duct. The Nernst equation explains why even small changes in extracellular K⁺ dramatically alter the resting membrane potential and cellular excitability.

Clinically, ECG monitoring is essential: hypokalemia produces U waves, ST depression, and T-wave flattening, while hyperkalemia progresses from peaked T waves to QRS widening to a sine-wave pattern. Management of hyperkalemia follows the stabilize → shift → remove paradigm (calcium gluconate, insulin/dextrose, then dialysis or binders), while hypokalemia requires K⁺ repletion with concurrent magnesium correction when hypomagnesemia is present. Advanced connections include the role of potassium in DKA management, digitalis toxicity, and inherited tubulopathies such as Bartter and Gitelman syndromes.